Gary Bird

Gary Bird was appointed Chief Executive Officer of LumaCina in July 2026, a global supplier and marketer of sterile injectable pharmaceutical products based in Perth, Australia. Bird brings more than 30 years of pharmaceutical leadership experience across Australia and the Asia-Pacific region, with expertise in commercial operations, pharmaceutical distribution, and healthcare partnerships. He has consistently built strong businesses by developing trusted customer relationships and delivering sustainable commercial outcomes.

Education & Board Service

Bird holds a degree in Medical Science from the University of Sydney and is a graduate of the Asialink Business Leaders Program from the University of Melbourne. Beyond his commercial role, he served as a board member of Heartkids Australia and was an elected member of local government as Councilor of the Municipality of Hunters Hill, NSW.

Career History

• Chief Executive Officer, LumaCina (2026–present)
• Chief Commercial Officer, Tissue Repair
• Managing Director, Medreich
• Senior leadership roles at Johnson & Johnson, Sanofi-Aventis, and Pharmacia
• Leadership positions at CROMA, Meda, Orion Pharma, and other pharmaceutical companies

What Bird could bring to LumaCina:

Bird's appointment reflects his proven capacity to establish global pharmaceutical operations and strengthen commercial partnerships. With deep expertise in commercial strategy, market expansion, and partnership-led growth accumulated over 30 years, he is positioned to expand LumaCina's sterile injectable portfolio across international markets while strengthening relationships with healthcare systems increasingly reliant on trusted pharmaceutical suppliers.